Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours

Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. The current evidence base for SABR for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldsmith, Christy, Gaya, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: e-Med 2012
Materias:
Tumour Board: Management with Lung Ablation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460596/
https://www.ncbi.nlm.nih.gov/pubmed/23023165
http://dx.doi.org/10.1102/1470-7330.2012.9015
_version_ 1782244957488152576
author Goldsmith, Christy
Gaya, Andrew
author_facet Goldsmith, Christy
Gaya, Andrew
author_sort Goldsmith, Christy
collection PubMed
description Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. The current evidence base for SABR for the treatment of primary and secondary lung tumours is appraised, and key ongoing trials are identified.
format Online
Article
Text
id pubmed-3460596
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher e-Med
record_format MEDLINE/PubMed
spelling pubmed-34605962012-11-21 Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours Goldsmith, Christy Gaya, Andrew Cancer Imaging Tumour Board: Management with Lung Ablation Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. The current evidence base for SABR for the treatment of primary and secondary lung tumours is appraised, and key ongoing trials are identified. e-Med 2012-09-28 /pmc/articles/PMC3460596/ /pubmed/23023165 http://dx.doi.org/10.1102/1470-7330.2012.9015 Text en © 2012 International Cancer Imaging Society
spellingShingle Tumour Board: Management with Lung Ablation
Goldsmith, Christy
Gaya, Andrew
Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
title Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
title_full Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
title_fullStr Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
title_full_unstemmed Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
title_short Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
title_sort stereotactic ablative body radiotherapy (sabr) for primary and secondary lung tumours
topic Tumour Board: Management with Lung Ablation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460596/
https://www.ncbi.nlm.nih.gov/pubmed/23023165
http://dx.doi.org/10.1102/1470-7330.2012.9015
work_keys_str_mv AT goldsmithchristy stereotacticablativebodyradiotherapysabrforprimaryandsecondarylungtumours
AT gayaandrew stereotacticablativebodyradiotherapysabrforprimaryandsecondarylungtumours

Ejemplares similares